Business
Coya Therapeutics Announces Conference Call to Report Results from an Investigator-Initiated Phase 2 Trial of Low-Dose Interleukin-2 in Patients with Mild to Moderate Alzheimer’s Disease
HOUSTON--(BUSINESS WIRE)-- Coya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics
About this update from Coya Therapeutics, Inc.
[{"type":"text","content":" HOUSTON--(BUSINESS WIRE)--\nCoya Therapeutics, Inc. (NASDAQ: COYA) (“Coya” or the “Company”), a clinical-stage biotechnology company developing biologics intended to enhance regulatory T cell (Treg) function, announces it will conduct a conference call on Tuesday, October 29, at 8am ET to discuss results from a placebo-controlled, investigator-initiated Phase 2 clinical trial of low-dose interleukin-2 (LD IL-2) in patients with mild to moderate Alzheimer's Disease (AD). These clinical results will be presented simultaneously via a poster on Tuesday, October 29, at the 17th Clinical Trials on Alzheimer’s Disease Conference (CTAD24) in Madrid, Spain.\n\nThe Phase 2 study was led by KOLs Dr. Alireza Faridar and Dr. Stanley Appel from the Houston Methodist Research Institute, and it received funding from the Alzheimer's Association, the Gates Foundation, and the National Institute on Aging, with additional support from Coya.\n\nDr. Faridar will present a summary of the clinical results on the conference call, and Coya’s Chief Business Officer and incoming Chief Executive Officer Arun Swaminathan, Ph.D. will discuss the Company’s strategy. A question-and-answer session will follow.\n\nThe conference call will be available through a live webcast that can be accessed here. Participants who may be interested in asking a question during the question-and-answer session can also join the call by dialing 1-866-807-9684 (domestic) or 1-412-317-5415 (international) and asking to join the Coya Therapeutics conference call.\n\nA webcast replay of the call will be available approximately one hour after the live call until October 29, 2025.\n\n\n\nEvent:\n\n\n \n \n\nCTAD Data Readout – Phase 2 Trial of LD-IL-2 in Patients with Mild to Moderate AD\n\n\n\n\n\n\n\n \n\n\n\nPresentation Date:\n\n\n \n \n\nTuesday, October 29, 2024\n\n\n\n\n\n\n\n \n\n\n\nTime:\n\n\n \n \n\n8:00 AM ET\n\n\n\n\n\n\n\n \n\n\n\nRegister for Conference Call:\n\n\n \n \n\nWebcast Link\n\n\n\n\nAbout Alzheimer’s Disease\n\nAlzheimer's disease is the most common cause of dementia, a general term for memory loss and other cognitive abilities serious enough to interfere with daily life. Alzheimer's disease accounts for up to 80% of dementia cases, affecting an estimated 5.7 million Americans. In more than 90% of people with Alzheimer’s, symptoms do not appear until after age...